drugset / Trial / NCT04217317
CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma
Phase 2
Terminated
6 enrolled
Wake Forest University Health Sciences
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if it is possible to give CPI-613 with the drug Bendamustine for 2 days every 28 days without causing severe side effects. In addition, this study will also test the safety of CPI-613 when given in combination with Bendamustine.
Timeline
- Start
- 2020-09-16
- Primary completion
- 2023-04-21
- Completion
- 2024-07-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bendamustine | Small molecule | 90 mg/m2 | Intravenous |
| Subject | CPI-613 | Small molecule | 2500 mg/m2 | Intravenous |